文献速递神经肿瘤

幕上低级别胶质瘤的对比增强:分子时代的经典预后因素

Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age.
PubMed 文献 · J Neurooncol · 2019-05-03

该回顾性研究纳入2000-2016年102例组织学确诊的低级别胶质瘤,分析对比增强(CE)与分子特征及预后的关系。结果显示CE存在于25%的术前MRI,IDH突变率64.6%,1p/19q共缺失率18.8%。多因素分析仅CE和IDH状态与总生存独立相关,CE在IDH突变非共缺失肿瘤中仍为显著预后因素。

要点

  • 低级别胶质瘤中CE见于25%的术前MRI,与IDH突变及1p/19q共缺失无显著相关性。
  • 多因素分析显示仅CE和IDH状态是总生存的独立预后因素。
  • 在IDH突变非共缺失肿瘤中,CE仍保持显著预后价值。

核心结论

  • 低级别胶质瘤的对比增强可提供预后信息,尤其在IDH突变非共缺失肿瘤中,但在IDH野生型胶质瘤中意义仍不确定。

研究设计与样本

  • 单中心回顾性研究,纳入2000-2016年组织学确诊的低级别胶质瘤102例,排除脊髓和脑干定位、仅活检的环形强化肿瘤及病历不完整者。

主要发现

  • 平均年龄42岁(±13.9岁),男性占63.6%,中位随访79.8个月。
  • 25%的术前MRI存在对比增强,25%患者根据Pignatti评分属高危。
  • 多数为星形细胞瘤(67%),87.2%接受手术切除。
  • IDH突变见于64.6%的肿瘤样本,18.8%存在1p/19q共缺失。
  • 单因素分析中,年龄、肿瘤大小>6 cm、CE、切除程度、Pignatti评分、IDH突变和1p/19q共缺失均与总生存显著相关;多因素分析仅CE和IDH状态独立相关。

临床怎么用

  • 对于低级别胶质瘤,术前MRI对比增强可作为预后评估的参考指标,尤其应结合IDH突变状态和1p/19q共缺失情况综合判断。

局限性

  • 回顾性单中心设计,样本量有限(n=102),结论需更大队列验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Contrast enhancement (CE) is found in 10-60% of low-grade gliomas. Its prognostic significance is controversial, and its correlation with IDH mutations and 1p/19q codeletion is elusive. The aim of this study is to investigate whether CE is associated with molecular characteristics of low-grade gliomas and uncover its prognostic value. MATERIALS AND METHODS: All confirmed histological cases of low-grade gliomas diagnosed at our institution between years 2000-2016 were reviewed (n = 102). Spinal and brainstem localization, only-biopsied tumours with ring-like enhancement and incomplete medical records were excluded. RESULTS: Mean age was 42 years ( ± 13.9 years), and 63.6% were male. The median follow-up time was 79.8 months. CE was present on 25% of preoperative MRI, and 25% of patients were considered high-risk according to Pignatti score. Most were astrocytomas (67%) and 87.2% were surgically removed. IDH mutation was found in 64.6% of tumour samples, and 18.8% had a 1p/19q codeletion. No subgroup differences were observed according to CE except for presurgical performance status and postoperative chemotherapy. IDH status and 1p/19q codeletion were evenly distributed. On univariate analysis, age, size > 6 cm, CE, extent of resection, Pignatti score, IDH mutation and 1p/19q codeletion were significantly associated to OS. On multivariate analysis, only CE and IDH status were independently associated to OS. CE remained a significant prognostic factor in IDH-mutant non-codeleted tumours when analysed by tumour subtype. CONCLUSION: CE in low-grade gliomas provides prognostic information in IDH-mutant non-codeleted tumours, although its meaning remains uncertain in IDH-wildtype gliomas.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Castet F, Alanya E, Vidal N, et al. Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age. J Neurooncol. 2019. PMID: 31054099. doi:10.1007/s11060-019-03183-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。